Real-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource UtilizationBusiness Wire • 01/25/22
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?Zacks Investment Research • 12/02/21
First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in EuropeBusiness Wire • 10/28/21
Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/25/21
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENTPRNewsWire • 09/13/21
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.PRNewsWire • 08/09/21
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENTBusiness Wire • 08/06/21
Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction with MedtronicPRNewsWire • 08/06/21
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/ShareBenzinga • 08/06/21